肺癌
医学
临床试验
癌症
肿瘤浸润淋巴细胞
免疫疗法
肺癌的治疗
肿瘤科
靶向治疗
重症监护医学
内科学
作者
Ali Nowroozi,Neda Khalili,Sepideh Razi,Mahsa Keshavarz-Fathi,Nima Rezaei
标识
DOI:10.1080/14712598.2022.2072206
摘要
Lung cancer is the leading cause of cancer death, with an estimated 1.8 million deaths contributing to this cancer in 2020. Despite advances in treatment options and various approaches being attempted, the survival rate remains low.In this review, we aim to provide an overview of the efficacy of tumor-infiltrating lymphocyte (TIL) therapy for lung cancer based on existing clinical trials. We also discuss the current challenges and future landscape of this treatment modality.Lung cancer can be a suitable candidate for TIL therapy due to its high mutational burden. Specifically, it has shown promising results for non-small cell lung cancer resistant to immune checkpoint inhibitors. Still, there are many restrictions associated with the ex vivo expansion and delivery of TILs, limiting their availability. For this reason, applying TIL for the treatment of lung cancer has not been extensively investigated yet and only a few clinical trials have shown favorable results of TIL therapy in patients with lung cancer. Thus, facilitating this costly, labor-intensive and time-consuming process is of utmost importance to increase the number of performed studies and to detect eligible patients who could benefit most from this treatment modality.
科研通智能强力驱动
Strongly Powered by AbleSci AI